In vivo 5FU-exposed human medullary thyroid carcinoma cells contain a chemoresistant CD133+ tumor-initiating cell subset

Thyroid

Volumn 24, Issue 3, 2014, Pages 520-532

  Kucerova, Lucia ^a   Feketeova, Lucia ^b   Kozovska, Zuzana ^a   Poturnajova, Martina ^a   Matuskova, Miroslava ^a   Nencka, Radim ^c   Babal, Pavel ^b  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; DOXORUBICIN; FLUOROURACIL; GIMERACIL; RALTITREXED; URACIL DERIVATIVE; VINCRISTINE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CANCER SURGERY; CARCINOGENESIS; CARCINOMA CELL; CD133 + CELL; CELL SUBPOPULATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID MEDULLARY CARCINOMA; XENOGRAFT;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GLYCOPROTEINS; HUMANS; NEOPLASTIC STEM CELLS; PEPTIDES; THYROID NEOPLASMS;

EID: 84896778994     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0277     Document Type: Article

References (53)

1. Pacini F, Castagna MG, Cipri C, Schlumberger M 2010 Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 22: 475-485.
2. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M 2008 New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:22-32.
3. Sugawara M, Geffner DL, Martinez D, Hershman JM 2009 Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes 16:367-372.
4. Tai D, Poon D 2010 Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers. J Oncol 2010:398564.
5. Regalbuto C, Frasca F, Pellegriti G, Malandrino P, Marturano I, Di Carlo I, Pezzino V 2012 Update on thyroid cancer treatment. Future Oncol 8:1331-1348.
6. Lin RY 2011 Thyroid cancer stem cells. Nat Rev Endocrinol 7:609-616.
7. Lloyd RV, Hardin H, Montemayor-Garcia C, Rotondo F, Syro LV, Horvath E, Kovacs K 2013 Stem cells and cancer stem-like cells in endocrine tissues. Endocrine Pathol 24: 1-10.
8. Boman BM, Wicha MS 2008 Cancer stem cells: a step toward the cure. J Clin Oncol 26:2795-2799.
9. Davies TF, Latif R, Minsky NC, Ma R 2011 Clinical review: the emerging cell biology of thyroid stem cells. J Clin Endocrinol Metab 96:2692-2702.
10. Malaguarnera R, Morcavallo A, Giuliano S, Belfiore A 2012 Thyroid cancer development and progression: emerging role of cancer stem cells. Minerva Endocrinol 37:103-115.
11. Keysar SB, Jimeno A 2010 More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 9:2450-2457.
12. Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, Pizzolanti G, Galluzzo A, Giordano C 2008 In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS ONE 3:e3544.
13. Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen KH, Chi CW, Chiou SH, Yang DM, Lee CH 2012 Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133 + cells. J Pharmacol Exp Ther 341:410-423.
14. Ke CC, Liu RS, Yang AH, Liu CS, Chi CW, Tseng LM, Tsai YF, Ho JH, Lee CH, Lee OK 2013 CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy. Eur J Nucl Med Mol Imaging 40:61-71.
15. Zhu W, Hai T, Ye L, Cote GJ 2010 Medullary thyroid carcinoma cell lines contain a self-renewing CD133 + population that is dependent on ret proto-oncogene activity. J Clin Endocrinol Metab 95:439-444.
16. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, Gulotta G, Dieli F, Giordano S, De Maria R, Stassi G 2010 Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 70:8874-8885.
17. Li W, Reeb AN, Sewell WA, Elhomsy G, Lin RY 2013 Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells. PLoS ONE 8:e65095.
18. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN 2006 Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760.
19. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabro E, Pastorino U, Sozzi G 2009 Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106:16281-16286.
20. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G 2007 Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1:389-402.
21. Longley DB, Harkin DP, Johnston PG 2003 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338.
22. Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S 2011 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics 12:251-265.
23. Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T 2001 Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37:1681-1687.
24. Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S, Ueda R 2005 The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 49:345-351.
25. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W 3rd, Dantzig AH 2005 The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 4:855-863.
26. Oguri T, Bessho Y, Achiwa H, Ozasa H, Maeno K, Maeda H, Sato S, Ueda R 2007 MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther 6:122-127.
27. Nambaru PK, Hubner T, Kock K, Mews S, Grube M, Payen L, Guitton J, Sendler M, Jedlitschky G, Rimmbach C, Rosskopf D, Kowalczyk DW, Kroemer HK, Weiss FU, Mayerle J, Lerch MM, Ritter CA 2011 Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metab Dispos 39:132-139.
28. Kucerova L, Matuskova M, Hlubinova K, Bohovic R, Feketeova L, Janega P, Babal P, Poturnajova M 2011 Bystander cytotoxicity in human medullary thyroid carcinoma cells mediated by fusion yeast cytosine deaminase and 5-fluorocytosine. Cancer Lett 311:101-112.
29. Kucerova L, Feketeova L, Matuskova M, Kozovska Z, Janega P, Babal P, Poturnajova M 2013 Local bystander effect induces dormancy in human medullary thyroid carcinoma model in vivo. Cancer Lett 335:299-305.
30. Kucerova L, Matuskova M, Pastorakova A, Tyciakova S, Jakubikova J, Bohovic R, Altanerova V, Altaner C 2008 Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 10:1071-1082.
31. Matuskova M, Baranovicova L, Kozovska Z, Durinikova E, Pastorakova A, Hunakova L, Waczulikova I, Nencka R, Kucerova L 2012 Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells. J Gene Med 14:776-787.
32. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wohrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C 2012 Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 12: 767-775.
33. Nguyen LV, Vanner R, Dirks P, Eaves CJ 2012 Cancer stem cells: an evolving concept. Nat Rev Cancer 12:133-143.
34. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, Prestegarden L, Rosland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R, Enger PO 2008 CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122:761-768.
35. Yang K, Chen XZ, Zhang B, Yang C, Chen HN, Chen ZX, Zhou ZG, Chen JP, Hu JK 2011 Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers 26:173-180.
36. Navarro-Alvarez N, Kondo E, Kawamoto H, Hassan W, Yuasa T, Kubota Y, Seita M, Nakahara H, Hayashi T, Nishikawa Y, Hassan RA, Javed SM, Noguchi H, Matsumoto S, Nakaji S, Tanaka N, Kobayashi N, Soto-Gutierrez A 2010 Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transplant 19:865-877.
37. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS 2006 Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma. Mol Cancer 5:67.
38. Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD 2010 A subpopulation of CD133( + ) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 289:151-160.
39. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T 2002 Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 38:167-176.
40. Patel A, Pluim T, Helms A, Bauer A, Tuttle RM, Francis GL 2004 Enzyme expression profiles suggest the novel tumoractivated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Cancer Chemother Pharmacol 53:409-414.
41. Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y, Kurumi Y, Tani T 2008 Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 61:587-594.
42. Okumura K, Shiomi H, Mekata E, Kaizuka M, Endo Y, Kurumi Y, Tani T 2006 Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. Oncol Rep 15:875-882.
43. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV 2000 Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327.
44. Miyatani T, Kurita N, Utsunomiya T, Iwata T, Nishioka M, Yoshikawa K, Higashijima J, Kashihara H, Takasu C, Fukushima M, Shimada M 2012 Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer. Cancer Lett 318:199-205.
45. Bronckaers A, Gago F, Balzarini J, Liekens S 2009 The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 29:903-953.
46. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH 2008 Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 3:e2637.
47. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, Samuel S, Kim MP, Lim SJ, Ellis LM 2009 Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69:1951-1957.
48. Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, Tall AR 2010 ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328: 1689-1693.
49. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, Katsumata N, Kang YK, Nishio K, Fujiwara Y 2006 Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 99:9-17.
50. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y 2008 Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 15:1981-2039.
51. Bidlingmaier S, Zhu X, Liu B 2008 The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl) 86:1025-1032.
52. Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ 2007 Tumour-initiating cells vs. cancer "stem" cells and CD133: what's in the name? Biochem Biophys Res Commun 355:855-859.
53. Pasquier E, Kavallaris M, Andre N 2010 Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7:455-465.